Research News

New Screening Approach Shows Promise

(May 5, 2015) Data from a large clinical trial shows that a personalized method for interpreting blood tests identifies more ovarian cancer cases than a generalized approach. The results from the study will be published in the Journal of Clinical Oncology. Using an algorithm to analyze changes in the... 

Oophorectomy Increases Breast Cancer Survival in BRCA1 Mutation Carriers

(April 29, 2015) A study published in JAMA Oncology last Saturday concluded that an oophorectomy, the surgery to remove ones ovaries, has a substantial impact on survival rates for those diagnosed with stage I or II breast cancer who also tested positive for the BRCA1 mutation. Involved in the study... 

New Recommendations for Ovarian Cancer Prevention

(April 16, 2015) The Society of Gynecologic Oncology has published recommendations for prevention of ovarian cancer in Cancer.  Strategies include oral contraceptive use and tubal sterilization, as well as genetic counseling and testing for women from high-risk families. Read the abstract here.  MORE

BRCA Cancer Risk Differs With Type and Location of Mutations

(April 15, 2015) Doctors have long recognized that women with mutations in two particular genes – BRCA1 and BRCA2 – have a higher risk of breast and ovarian cancer. Now they are starting to figure out which mutations are worse than others. They have even discovered that some of these mutations may... 

Rucaparib Receives Breakthrough Therapy Designation from FDA

(April 14, 2015) The FDA granted breakthrough therapy designation to rucaparib as monotherapy for patients with advanced ovarian cancer. Rucaparib is an oral, small-molecule PARP inhibitor developed for the treatment of platinum-sensitive ovarian cancer, specifically in patients with tumors that have... 

OCRF Now Accepting Applications for 2016 Research Grants

We are now accepting letters of intent for all research grants. LOIs are due May 8, 2015. Click here for more information.  MORE

Microenvironment Regulates Tumor Suppressor miRNA

Ernst Lengyel, MD, PhD (April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells. The direct interaction of the ovarian cancer cells with mesothelial cells, which cover the surface of the omentum, caused... 

Population Distribution of Lifetime Risk of Ovarian Cancer in the US

(April 1, 2015) A study published in Cancer Epidemiology, Biomarkers and Prevention looks at ovarian cancer risk in the general population.  In U.S. women, lifetime risk of ovarian cancer is 1.37%, but some women are at a substantially lower or higher ovarian cancer risk due to both genetic and lifestyle... 

Intraperitoneal Chemo Associated with Long-Term Survival Advantage

(March 27, 2015) According to research published this week in the Journal of Clinical Oncology, intraperitoneal (IP) chemotherapy is associated with a long-term survival advantage in ovarian cancer.  The advantage of IP over intravenous chemotherapy extends beyond 10 years, and IP therapy enhanced survival... 

Decisions on a Knife-Edge: Risks and Benefits of Fallopian Tube Removal

(March 20, 2015) This excellent, accessible piece in Mosaic Magazine, “Decisions on a Knife-Edge,” explores the difficult choices high-risk women face when considering how to decrease their chances of developing ovarian cancer.  Removing only the fallopian tubes will avoid forcing a woman...